Emel BAŞAR, Halit PAZARLI, Alp KAYIRAN

Esansiyel blefarospazma bağlı fonksiyonel körlüğün kimyasal denevasyonla tedavisi

Periyodik BT-A enjeksiyonu ile sağlanan kimyasal denervasyon blefarospazmı kontrol etmede ve fonksiyonel körlüğü engellemede tatminkar bir alternatiftir. Ilımlı, geçici ve lokal komplikasyonlarına karşı hastalar bu tedavi yöntemini tercih etmektedir.

Chemical denervation for the treatment of functional blindness due to essential blepharospasm

Background.- To evaluate the treatment of functional blindness due to prolonged eyebrow and eyelid spasm and involuntary eyelid closure in essential blepharospasm with Botulinum toxin-A. Design.- 7 patients (5 female, 2 male, average age over 35 years) with functional blindness due to essential blepharospasm were treated with Botulinum toxin (BT-A) as an outpatient procedure in the oculoplastic unit of Department of Ophthalmology, Cerrahpaşa Medical Faculty, Istanbul University. BT-A was injected subcutaneously up to different sites in the eyebrow region, medial and lateral aspects of the upper lids and lateral aspect of the lower lid as a total of 15-25 units for each eye. Mean follow-up time was 6,8 months. Results.- BT-A treatment resulted in functional improvement to open the eyelids enough to maintain daily life without visual restrictions. Mean duration of the effect was 14.5 weeks. No systemic side effects were observed. Lid ecchymosis in 3 patients and symptomatic dry eye in one patient were noted during the follow-up period. Conclusion.- BT-A treatment can improve the functional blindness in patients with essential blepharospasm temporarily by decreasing debiliating and squeezing spasms of the eyelids and eyebrows.

PDF

___

1.Tucha A, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm, Acta Neurol Sçand 2001; 103: 49-52.
2.Patel BC, Anderson RL. Essential blepharospasm and related disease. Clinical nodules for Ophthalmology, Focal points, XVÜL;5, June 2000, American Academy of Ophthalmology
3.Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present and future.Ophthal Plast Reconstr Surg 1998; 14: 305-317.
4.Berlin AJ, Cassen İH, DeNelsky G, Hanson MR, 9. Sweeney PJ. Benign essential belpharospasm treated with botulinum toxin. Cteve Clin J Med 1987; 54: 421-426.
5.McCarm JD, Uğurbaş SH, Goldberg RA. Benign 10. Essential Blepharospasm. International Ophthalmology Clinics 2002; 42: 113-121.
6.Yağcı A, Köse S, Kayıkcıoğlu Ö, Pamukçu K. Esansiyel blefarospasmli hastalarda botolismus- toksin uygulanması MN Oftalmoloji 19Ş8; 5:138-140.
7.Wutthiphan S, Kowal L, O'Day J, Jones S, Price J. Diplopia following subcutaneous injection of botulinum A toxin for facial spasms J Pediatr Ophthalmol Strabismus 1997; 34: 229-234.
8.Price J, O'Day J Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm. Aust N Z J Ophthalmol 1994; 22: 255-260.
9.Dutton JJ, Buckley EG. Long term results and complications of botulinum. A toxin in the treatment of blepharospasm. Ophthalmology 1998; 11: 1529-1534.
10.Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time Can J Ophthalmol 2001; 36: 398-403.